KOBE, Japan, Oct. 27 — Carna Biosciences, Inc. (“Carna”) announced on October 27, 2008, the signing of a Distribution Agreement with Shanghai Universal Biotech Company (“SUBC”). Under the terms of this Agreement, SUBC will become the exclusive distributor of Carna’s Protein Kinases within China. With China’s emergence as a strong market opportunity, particularly in the life sciences, major biopharmaceutical companies have now established research and production facilities in Shanghai and other regions of China. These facilities seek and require goods to support their internal drug discovery programs. Carna is an established global provider of protein kinases used in the discovery and development of the important class of drugs known as kinase inhibitors. The Agreement with SUBC makes these products readily available to Chinese researchers via SUBC’s strong distribution channels. In addition to major biopharmaceutical presence, tax incentives provided by the Chinese government have provided a fertile environment for the establishment of bio-venture companies and CRO. The Agreement between Carna and SUBC, with its offices in the major cities of Shanghai and Beijing, is anticipated to lead to significantly increased sales opportunities for Carna and further establish its reputation as a global provider of protein kinases.